BioSpace News Archive

Loxo Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to LOXO-292

National Institute for Innovation in Manufacturing Biopharmaceuticals Funds UMB Researcher

Days after receiving a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on COPD treatment, GlaxoSmithKline released data that showed the same medication was a superior treatment in severe eosinophilic asthma in patients with similar blood eosinophil counts.

It’s been a hot year for biotech initial public offerings (IPOs). Two recent announced offerings, Kodiak Sciences in Palo Alto and Guardant Health in Redwood City mark the fourteenth and fifteenth life sciences IPOs in the San Francisco Bay Area this year.

The opposition to Takeda Pharmaceutical acquiring Shire has taken on another dimension with a prominent member of the family that created the Japanese pharmaceutical company speaking publicly against the deal.

As the weather cools down, let’s look back at this summer’s most popular career advice on BioSpace.

Cellmid Limited today advised that the Share Purchase Plan (“SPP”) announced on 31 July 2018 with an offer price of $0.38 has now closed.

Dream-Kicker.com to offer donation-based, cryptocurrency support for cutting-edge regenerative medicine and medical equipment

A randomized, placebo and gold-standard controlled clinical trial, investigating the treatment of incipient buccal caries lesions with CURODONT™ REPAIR was presented at the IADR 2018 in London. In this study Prof. Krejci and his team at the University of Geneva showed that the use of CURODONT™ REPAIR is superior to that of fluoride varnish or a placebo treatment.

Cooperative effort will ensure top quality plants for medical treatment